Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing
Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203